|
1
|
Malhotra J, Jabbour SK and Aisner J:
Current state of immunotherapy for non-small cell lung cancer.
Transl Lung Cancer Res. 6:196–211. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liao BC, Lin CC, Lee JH and Yang JC:
Optimal management of EGFR-mutant non-small cell lung cancer with
disease progression on first-line tyrosine kinase inhibitor
therapy. Lung Cancer. 110:7–13. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu X, Lu X, Zhen F, Jin S, Yu T, Zhu Q,
Wang W, Xu K, Yao J and Guo R: LINC00665 induces acquired
resistance to gefitinib through recruiting EZH2 and activating
PI3K/AKT pathway in NSCLC. Mol Ther Nucleic Acids. 16:155–161.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li L, Han R, Xiao H, Lin C, Wang Y, Liu H,
Li K, Chen H, Sun F, Yang Z, et al: Metformin sensitizes
EGFR-TKI-resistant human lung cancer cells in vitro and in vivo
through inhibition of IL-6 signaling and EMT reversal. Clin Cancer
Res. 20:2714–2726. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang Y, Wu Z, Yu H, Wang H, Liu G, Wang S
and Ji X: Chinese herbal medicine wenxia changfu formula reverses
cell adhesion--mediated drug resistance via the integrin
β1-PI3K-AKT pathway in lung cancer. J Cancer. 10:293–304. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen P, Huang HP, Wang Y, Jin J, Long WG,
Chen K, Zhao XH, Chen CG and Li J: Curcumin overcome primary
gefitinib resistance in non-small-cell lung cancer cells through
inducing autophagy-related cell death. J Exp Clin Cancer Res.
38:2542019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Almaaytah A, Farajallah A, Abualhaijaa A
and Al-Balas Q: A3, a Scorpion venom derived peptide analogue with
potent antimicrobial and potential antibiofilm activity against
clinical isolates of multi-drug resistant gram positive bacteria.
Molecules. 23:E16032018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cao F, Gong YB, Kang XH, Lu ZH, Wang Y,
Zhao KL, Miao ZH, Liao MJ and Xu ZY: Degradation of MCL-1 by
bufalin reverses acquired resistance to osimertinib in EGFR-mutant
lung cancer. Toxicol Appl Pharmacol. 379:1146622019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hou ZY, Tong XP, Peng YB, Zhang BK and Yan
M: Broad targeting of triptolide to resistance and sensitization
for cancer therapy. Biomed Pharmacother. 104:771–780. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qiu D and Kao PN: Immunosuppressive and
anti-inflammatory mechanisms of triptolide, the principal active
diterpenoid from the Chinese medicinal herb Tripterygium
wilfordii Hook. f. Drugs R D. 4:1–18. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meng G, Wang W, Chai K, Yang S, Li F and
Jiang K: Combination treatment with triptolide and
hydroxycamptothecin synergistically enhances apoptosis in A549 lung
adenocarcinoma cells through PP2A-regulated ERK, p38 MAPKs and Akt
signaling pathways. Int J Oncol. 46:1007–1017. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu B, Guo X, Mathew S, Armesilla AL,
Cassidy J, Darling JL and Wang W: Triptolide simultaneously induces
reactive oxygen species, inhibits NF-kappaB activity and sensitizes
5-fluorouracil in colorectal cancer cell lines. Cancer Lett.
291:200–208. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xie CQ, Zhou P, Zuo J, Li X, Chen Y and
Chen JW: Triptolide exerts pro-apoptotic and cell cycle arrest
activity on drug-resistant human lung cancer A549/Taxol cells via
modulation of MAPK and PI3K/Akt signaling pathways. Oncol Lett.
12:3586–3590. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ho JN, Byun SS, Lee S, Oh JJ, Hong SK, Lee
SE and Yeon JS: Synergistic antitumor effect of triptolide and
cisplatin in cisplatin resistant human bladder cancer cells. J
Urol. 193:1016–1022. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li F, Zhao D, Yang S, Wang J, Liu Q, Jin X
and Wang W: ITRAQ-Based proteomics analysis of triptolide on human
A549 lung adenocarcinoma cells. Cell Physiol Biochem. 45:917–934.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kourtidis A, Lu R, Pence LJ and
Anastasiadis PZ: A central role for cadherin signaling in cancer.
Exp Cell Res. 358:78–85. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weng CH, Chen LY, Lin YC, Shih JY, Lin YC,
Tseng RY, Chiu AC, Yeh YH, Liu C, Lin YT, et al:
Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per
se is a common mechanism for acquired resistance to EGFR TKI.
Oncogene. 38:455–468. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rastogi I, Rajanna S, Webb A, Chhabra G,
Foster B, Webb B and Puri N: Mechanism of c-Met and EGFR tyrosine
kinase inhibitor resistance through epithelial mesenchymal
transition in non-small cell lung cancer. Biochem Biophys Res
Commun. 477:937–944. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Iderzorig T, Kellen J, Osude C, Singh S,
Woodman JA, Garcia C and Puri N: Comparison of EMT mediated
tyrosine kinase inhibitor resistance in NSCLC. Biochem Biophys Res
Commun. 496:770–777. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yin J, Hu W, Pan L, Fu W, Dai L, Jiang Z,
Zhang F and Zhao J: Let7 and miR17 promote self-renewal and drive
gefitinib resistance in non-small cell lung cancer. Oncol Rep.
42:495–508. 2019.PubMed/NCBI
|
|
22
|
Fiore M, Trecca P, Perrone G, Amato M,
Righi D, Trodella L, D'Angelillo RM and Ramella S: Histologic
transformation to small-cell lung cancer following gefitinib and
radiotherapy in a patient with pulmonary adenocarcinoma. Tumori.
105:NP12–NP16. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang J, Sun L, Cui J, Wang J, Liu X, Aung
TN, Qu Z, Chen Z, Adelson DL and Lin L: Yiqi chutan tang reduces
gefitinib-induced drug resistance in non-small-cell lung cancer by
targeting apoptosis and autophagy. Cytometry A. 97:70–77. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Meng J, Chang C, Chen Y, Bi F, Ji C and
Liu W: EGCG overcomes gefitinib resistance by inhibiting autophagy
and augmenting cell death through targeting ERK phosphorylation in
NSCLC. Onco Targets Ther. 12:6033–6043. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang R, Ma X, Su S and Liu Y: Triptolide
antagonized the cisplatin resistance in human ovarian cancer cell
line A2780/CP70 via hsa-mir-6751. Future Med Chem. 10:1947–1955.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Han Y, Huang W, Liu J, Liu D, Cui Y, Huang
R, Yan J and Lei M: Triptolide inhibits the AR signaling pathway to
suppress the proliferation of enzalutamide resistant prostate
cancer cells. Theranostics. 7:1914–1927. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bean J, Brennan C, Shih JY, Riely G, Viale
A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, et al: MET
amplification occurs with or without T790M mutations in EGFR mutant
lung tumors with acquired resistance to gefitinib or erlotinib.
Proc Natl Acad Sci USA. 104:20932–20937. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schueler J, Tschuch C, Klingner K, Bug D,
Peille AL, de Koning L, Oswald E, Klett H and Sommergruber W:
Induction of acquired resistance towards EGFR inhibitor gefitinib
in a patient-derived xenograft model of non-small cell lung cancer
and subsequent molecular characterization. Cells. 8:E7402019.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Suda K, Mizuuchi H, Maehara Y and
Mitsudomi T: Acquired resistance mechanisms to tyrosine kinase
inhibitors in lung cancer with activating epidermal growth factor
receptor mutation-diversity, ductility, and destiny. Cancer
Metastasis Rev. 31:807–814. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II,
Yang SH, Kim CH and Lee JC: Epithelial to mesenchymal transition
derived from repeated exposure to gefitinib determines the
sensitivity to EGFR inhibitors in A549, a non-small cell lung
cancer cell line. Lung Cancer. 63:219–226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jakobsen KR, Demuth C, Sorensen BS and
Nielsen AL: The role of epithelial to mesenchymal transition in
resistance to epidermal growth factor receptor tyrosine kinase
inhibitors in non-small cell lung cancer. Transl Lung Cancer Res.
5:172–182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Asakura T, Yamaguchi N, Ohkawa K and
Yoshida K: Proteasome inhibitor-resistant cells cause EMT-induction
via suppression of E-cadherin by miR-200 and ZEB1. Int J Oncol.
46:2251–2260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gloushankova NA, Zhitnyak IY and Rubtsova
SN: Role of epithelial-mesenchymal transition in tumor progression.
Biochemistry (Mosc). 83:1469–1476. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Papiewska-Pajak I, Kowalska MA and Boncela
J: Expression and activity of SNAIL transcription factor during
epithelial to mesenchymal transition (EMT) in cancer progression.
Postepy Hig Med Dosw (Online). 70:968–980. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shimokawa M, Haraguchi M, Kobayashi W,
Higashi Y, Matsushita S, Kawai K, Kanekura T and Ozawa M: The
transcription factor Snail expressed in cutaneous squamous cell
carcinoma induces epithelial-mesenchymal transition and
down-regulates COX-2. Biochem Biophys Res Commun. 430:1078–1082.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Richardson AM, Havel LS, Koyen AE, Konen
JM, Shupe J, Wiles WG IV, Martin WD, Grossniklaus HE, Sica G,
Gilbert-Ross M and Marcus AI: Vimentin is required for lung
adenocarcinoma metastasis via heterotypic tumor
cell-cancer-associated fibroblast interactions during collective
invasion. Clin Cancer Res. 24:420–432. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang M and Xin W: Matrine inhibiting
pancreatic cells epithelial-mesenchymal transition and invasion
through ROS/NF-κB/MMPs pathway. Life Sci. 192:55–61. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun Q, Yang Z, Li P, Wang X, Sun L, Wang
S, Liu M and Tang H: A novel miRNA identified in GRSF1 complex
drives the metastasis via the PIK3R3/AKT/NF-κB and TIMP3/MMP9
pathways in cervical cancer cells. Cell Death Dis. 10:6362019.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Han B, Zhang YY, Xu K, Bai Y, Wan LH, Miao
SK, Zhang KX, Zhang HW, Liu Y and Zhou LM: NUDCD1 promotes
metastasis through inducing EMT and inhibiting apoptosis in
colorectal cancer. Am J Cancer Res. 8:810–823. 2018.PubMed/NCBI
|
|
41
|
Hu JZ, Wang XK, Cao Y, Li DZ, Wu TD, Zhang
T, Xu DQ and Lu HB: Tetramethylpyrazine facilitates functional
recovery after spinal cord injury by inhibiting MMP2, MMP9, and
vascular endothelial cell apoptosis. Curr Neurovasc Res.
14:110–116. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hsu PC, Liao YF, Lin CL, Lin WH, Liu GY
and Hung HC: Vimentin is involved in peptidylarginine deiminase
2-induced apoptosis of activated Jurkat cells. Mol Cells.
37:426–34. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang L, Tang L, Dai F, Meng G, Yin R, Xu X
and Yao W: Raf-1/CK2 and RhoA/ROCK signaling promote TNF-α-mediated
endothelial apoptosis via regulating vimentin cytoskeleton.
Toxicology. 389:74–84. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Qiang Z, Jun-Jie L, Hai W, Hong L, Hong L,
Bing-Xi L, Lei C, Wei X, Ya-Wei L, Huang A, Song-Tao Q and Yun-Tao
L: TPD52L2 impacts proliferation, invasiveness and apoptosis of
glioblastoma cells via modulation of wnt/β-catenin/snail signaling.
Carcinogenesis. 39:214–224. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bao X, Ren T, Huang Y, Ren C, Yang K,
Zhang H and Guo W: Bortezomib induces apoptosis and suppresses cell
growth and metastasis by inactivation of Stat3 signaling in
chondrosarcoma. Int J Oncol. 50:477–486. 2017. View Article : Google Scholar : PubMed/NCBI
|
